2.23

5.69% 0.12

After Hours: 2.23

Inhibikase Therapeutics Inc (IKT)

Overview News Price History Financials Discussions Forecast Stock Split

Inhibikase Therapeutics Inc stock is traded at $2.23, with a volume of 1.07M. It is up +5.69% in the last 24 hours and up +21.86% over the past month. Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Previous Close:

$2.11

Open:

$2.11

24h Volume:

1.07M

Relative Volume:

1.20

Market Cap:

$350.18M

Revenue:

$79,600

Net Income/Loss:

$-48.26M

P/E Ratio:

-4.5307

EPS:

-0.4922

Net Cash Flow:

$-28.24M

1W Performance:

+13.78%

1M Performance:

+21.86%

6M Performance:

+35.15%

1Y Performance:

+21.20%

1-Day Range:

$2.10

$2.26

1-Week Range:

$1.93

$2.36

52-Week Range:

$1.33

$2.36

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Name

Inhibikase Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (603)

Phone

(302) 295-3800

Address

1000 N. WEST STREET, SUITE 1200, WILMINGTON

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

IKT's Discussions on Twitter

Compare IKT vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IKT Inhibikase Therapeutics Inc	2.23	331.34M	79,600	-48.26M	-28.24M	-0.4922
VRTX Vertex Pharmaceuticals Inc	480.50	123.26B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.15	70.94B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.19	53.84B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	180.39	39.58B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	272.67	35.71B	4.29B	577.22M	641.34M	4.2086

Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-04-26	Initiated	Ladenburg Thalmann	Buy
Jan-21-26	Initiated	BofA Securities	Buy
Dec-26-25	Initiated	H.C. Wainwright	Buy
Dec-11-25	Initiated	Cantor Fitzgerald	Overweight
Feb-12-25	Downgrade	H.C. Wainwright	Buy → Neutral

Inhibikase Therapeutics Inc Stock (IKT) Latest News

12:08 PM

Frontier tech research, news & data - MLQ.ai

12:08 PM

Jul 18, 2026

RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics - Bitget

Jul 18, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat

Jul 18, 2026

Jul 17, 2026

RA Capital discloses 25M-share stake in Inhibikase Therapeutics (IKT) - Stock Titan

Jul 17, 2026

RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase - Stock Titan

Jul 17, 2026

Jul 16, 2026

IKT Receives FDA Orphan Designation for Pulmonary Arterial Hyper - GuruFocus

Jul 16, 2026

Jul 15, 2026

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - Sahm

Jul 15, 2026

Inhibikase raises $50M to fund PAH program - TipRanks

Jul 15, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Brokerages - MarketBeat

Jul 15, 2026

Jul 14, 2026

Inhibikase Therapeutics Shares Rise on $50M At‐the‐Market Share Sale - Moomoo

Jul 14, 2026

Inhibikase raises $50 million through stock sale to RA Capital - Investing.com

Jul 14, 2026

Inhibikase Therapeutics Sells $50M of Stock to RA Capital via ATM Facility - TradingView

Jul 14, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH - MarketBeat

Jul 14, 2026

Inhibikase raises $50 million through stock sale to RA Capital By Investing.com - Investing.com Canada

Jul 14, 2026

Inhibikase Therapeutics (Nasdaq: IKT) sells 25M shares for $50M cash - Stock Titan

Jul 14, 2026

Inhibikase's $50M share sale could support Phase 3 PAH readout - Stock Titan

Jul 14, 2026

Inhibikase Therapeutics (NASDAQ:IKT) Shares Down 3.9%Here's What Happened - MarketBeat

Jul 14, 2026

Jul 10, 2026

Inhibikase Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Stock as Cash Burn ContinuesAnnual Earnings Summary - dars.gov.et

Jul 10, 2026

Jul 07, 2026